bioRxiv preprint doi: https://doi.org/10.1101/2021.08.18.456892; this version posted August 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies Author names and affiliations Justin Hwang4,5,**,*, Rand Arafeh1,2,3,**, Ji-Heui Seo1,2,3,**, Sylvan C. Baca1,2,3, Megan Ludwig7, Taylor E. Arnoff8, Camden Richter1,2,3, Hannah E. Bergom5, Sean McSweeney5, Jonathan P. Rennhack1,2,3, Sarah A. Klingenberg5, Alexander TM. Cheung3,10, Jason Kwon1,2,3, Jonathan So1,2,3, Steven Kregel9, Eliezer M. Van Allen1,2,3, Justin M. Drake4,6, Mathew L. Freedman1,2,3, William C. Hahn1,2,3,* 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA, 02215, USA 2Harvard Medical School, Boston MA, 02115, USA 3Broad Institute of MIT and Harvard, Cambridge MA, 02142, USA 4Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, 55455; USA 5Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455; USA 6Department of Pharmacology and Urology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455; USA 7Department of Pharmacology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA. 8Warren Alpert Medical School of Brown University, Providence, RI, 02903, USA 9Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA 10NYU Grossman School of Medicine, New York, NY **Co-first Authors *Co-corresponding Authors Corresponding authors: William C Hahn, M.D., Ph.D. Dana-Farber Cancer Institute Department of Medical Oncology 450 Brookline Avenue; D1538 Boston, MA 02215 tel: 617-632-2641; fax: 617-632-4005 email:
[email protected] Justin Hwang, Ph.D.